Neoadjuvant drug combo for locally advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs before standard treatment for locally advanced cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cervical cancer called squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
- Your cancer is locally advanced, meaning it has spread within the pelvis but not to distant organs, and your tumor is at least 4 cm.
- You have not had any prior cancer treatment.
- You are between 18 and 65 years old.
- You are generally healthy and able to care for yourself (ECOG score 0 or 1).
- You can provide a tumor tissue sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery for cervical cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes, and it is given as a neoadjuvant (before-surgery) approach.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests two immune-boosting drugs (iparomlimab and tuvonralimab) combined with standard chemotherapy given before surgery for locally advanced cervical cancer. The goal is to shrink the cancer and improve survival chances.
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.